Cargando…
Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
BACKGROUND: Analysis of melanomas for actionable mutations has become the standard of care. Recently, a classification scheme has been proposed that categorizes BRAF mutations based on their mechanisms for activation of the MAPK pathway. METHODS: In this analysis BRAF, KIT, NRAS, and PIK3CA mutation...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612071/ https://www.ncbi.nlm.nih.gov/pubmed/31277584 http://dx.doi.org/10.1186/s12885-019-5864-1 |
_version_ | 1783432816160145408 |
---|---|
author | Lokhandwala, Parvez M. Tseng, Li-Hui Rodriguez, Erika Zheng, Gang Pallavajjalla, Aparna Gocke, Christopher D. Eshleman, James R. Lin, Ming-Tseh |
author_facet | Lokhandwala, Parvez M. Tseng, Li-Hui Rodriguez, Erika Zheng, Gang Pallavajjalla, Aparna Gocke, Christopher D. Eshleman, James R. Lin, Ming-Tseh |
author_sort | Lokhandwala, Parvez M. |
collection | PubMed |
description | BACKGROUND: Analysis of melanomas for actionable mutations has become the standard of care. Recently, a classification scheme has been proposed that categorizes BRAF mutations based on their mechanisms for activation of the MAPK pathway. METHODS: In this analysis BRAF, KIT, NRAS, and PIK3CA mutations were examined by next generation sequencing (NGS) in 446 melanomas in a clinical diagnostic setting. KRAS and HRAS were also analyzed to elucidate coexisting BRAF and RAS mutations. BRAF mutations were categorized into class-1 (kinase-activated, codon 600), class-2 (kinase-activated, non-codon 600) and class-3 (kinase-impaired), based on the newly proposed classification scheme. RESULTS: NGS demonstrated high analytic sensitivity. Among 355 mutations detected, variant allele frequencies were 2–5% in 21 (5.9%) mutations and 2–10% in 47 (13%) mutations. Mutations were detected in BRAF (42%), NRAS (25%), KIT (4.9%) and PIK3CA (2.7%). The incidence of class-1, class-2 and class-3 mutations were 33% (26% p.V600E and 6.1% p.V600K), 3.1 and 4.9% respectively. With a broader reportable range of NGS, class-1, class-2 and class-3 mutations accounted for 77, 7.4 and 12% of all BRAF mutations. Class-3 mutations, commonly affecting codons 594, 466 and 467, showed a higher incidence of coexisting RAS mutations, consistent with their RAS-dependent signaling. Significant association with old age and primary tumors of head/neck/upper back suggest chronic solar damage as a contributing factor for melanomas harboring BRAF p.V600K or class-3 mutations. CONCLUSION: This study categorizes the range, frequency, coexisting driver mutations and clinical characteristics of the three classes of BRAF mutations in a large cohort of melanomas in a clinical diagnostic setting. Further prospective studies are warranted to elucidate the clinical outcomes and benefits of newly developed targeted therapy in melanoma patients carrying each class of BRAF mutation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5864-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6612071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66120712019-07-16 Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing Lokhandwala, Parvez M. Tseng, Li-Hui Rodriguez, Erika Zheng, Gang Pallavajjalla, Aparna Gocke, Christopher D. Eshleman, James R. Lin, Ming-Tseh BMC Cancer Research Article BACKGROUND: Analysis of melanomas for actionable mutations has become the standard of care. Recently, a classification scheme has been proposed that categorizes BRAF mutations based on their mechanisms for activation of the MAPK pathway. METHODS: In this analysis BRAF, KIT, NRAS, and PIK3CA mutations were examined by next generation sequencing (NGS) in 446 melanomas in a clinical diagnostic setting. KRAS and HRAS were also analyzed to elucidate coexisting BRAF and RAS mutations. BRAF mutations were categorized into class-1 (kinase-activated, codon 600), class-2 (kinase-activated, non-codon 600) and class-3 (kinase-impaired), based on the newly proposed classification scheme. RESULTS: NGS demonstrated high analytic sensitivity. Among 355 mutations detected, variant allele frequencies were 2–5% in 21 (5.9%) mutations and 2–10% in 47 (13%) mutations. Mutations were detected in BRAF (42%), NRAS (25%), KIT (4.9%) and PIK3CA (2.7%). The incidence of class-1, class-2 and class-3 mutations were 33% (26% p.V600E and 6.1% p.V600K), 3.1 and 4.9% respectively. With a broader reportable range of NGS, class-1, class-2 and class-3 mutations accounted for 77, 7.4 and 12% of all BRAF mutations. Class-3 mutations, commonly affecting codons 594, 466 and 467, showed a higher incidence of coexisting RAS mutations, consistent with their RAS-dependent signaling. Significant association with old age and primary tumors of head/neck/upper back suggest chronic solar damage as a contributing factor for melanomas harboring BRAF p.V600K or class-3 mutations. CONCLUSION: This study categorizes the range, frequency, coexisting driver mutations and clinical characteristics of the three classes of BRAF mutations in a large cohort of melanomas in a clinical diagnostic setting. Further prospective studies are warranted to elucidate the clinical outcomes and benefits of newly developed targeted therapy in melanoma patients carrying each class of BRAF mutation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5864-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-05 /pmc/articles/PMC6612071/ /pubmed/31277584 http://dx.doi.org/10.1186/s12885-019-5864-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lokhandwala, Parvez M. Tseng, Li-Hui Rodriguez, Erika Zheng, Gang Pallavajjalla, Aparna Gocke, Christopher D. Eshleman, James R. Lin, Ming-Tseh Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing |
title | Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing |
title_full | Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing |
title_fullStr | Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing |
title_full_unstemmed | Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing |
title_short | Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing |
title_sort | clinical mutational profiling and categorization of braf mutations in melanomas using next generation sequencing |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612071/ https://www.ncbi.nlm.nih.gov/pubmed/31277584 http://dx.doi.org/10.1186/s12885-019-5864-1 |
work_keys_str_mv | AT lokhandwalaparvezm clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing AT tsenglihui clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing AT rodriguezerika clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing AT zhenggang clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing AT pallavajjallaaparna clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing AT gockechristopherd clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing AT eshlemanjamesr clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing AT linmingtseh clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing |